ANTIBODY SPECIFICALLY BINDING TO SARS-CoV-2 VARIANTS
A human antibody with enhanced binding affinity to COVID-19 virus variants addresses the challenge of mutations by facilitating rapid detection and effective treatment, leveraging nucleic acid molecules and host cells for production.
Patent Information
- Application Number
- KR1020210169632
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-12-01
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-12-01
AI Technical Summary
There is an urgent need for effective diagnostic methods and treatments for COVID-19 virus infections, particularly against variants, as current vaccines and treatments are inadequate due to mutations in the spike proteins of the virus, and there is a lack of approved treatments or vaccines, with no established evaluation system for developing substances.
Development of a human antibody specific to the COVID-19 virus or its variants, along with fragments having immunological activity, including nucleic acid molecules, vectors, and host cells for production, to facilitate detection, prevention, and treatment of the virus.
The antibody exhibits high binding affinity to various COVID-19 virus variants, enabling rapid detection and effective prevention or treatment of infections, supporting diagnostic and epidemiological investigations.
Smart Images

Figure 112021139083539-PAT00007_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a human antibody against a novel coronavirus (COVID-19 virus: SARS-CoV-2) and variants thereof, or a fragment having the immunological activity thereof. Background Technology
[0002] Coronaviruses are enveloped viruses with a single-stranded positive RNA genome that have been isolated from various animals, including humans, since their first discovery in 1937. Coronaviruses can be divided into four groups. Among these, alpha-coronaviruses and beta-coronaviruses primarily infect mammals, while gamma-coronaviruses and delta-coronaviruses infect birds; however, there have recently been confirmed cases of delta-coronavirus infection in pigs. Coronaviruses can transmit infections between species. Representative examples include the SARS coronavirus, which caused the Severe Acute Respiratory Syndrome (SARS) epidemic that swept the globe in 2003, and the MERS coronavirus, which spread domestically in 2015; both of these viruses are known to have originated from bats. Among mammals, bats possess the ability to fly, allowing them to inhabit a wide range of areas. Due to their characteristic of living in groups in confined spaces such as caves, if a single individual becomes infected with a virus, the infection spreads to the group, and they can spread the infection to other animals through movement over wide areas via flight. Furthermore, unlike other mammals, bats have a high body temperature, which provides resistance to viruses; thus, bats acting as coronavirus hosts can remain unaffected and continue to transmit the infection. As described above, coronaviruses are capable of interspecies transmission, and it has been confirmed that novel coronaviruses originating from bats can cause significant problems by transmitting to humans. Therefore, the development of effective diagnostic methods and treatments to detect novel bat-derived coronaviruses is urgent.Currently, research on antiviral agents is actively underway both domestically and internationally. Non-specific antiviral agents that have demonstrated efficacy in clinical trials include type I interferon and ribavirin, although they have been reported to have a viral suppression effect only during the early stages of infection. Additionally, treatments for MERS coronavirus and SARS coronavirus are receiving attention due to the increasing need for their development (A. Zumla et al., Nature Reviews Drug Discovery, 15:327-347, 2016). However, there are currently no approved treatments or vaccines in Korea or abroad, and since an evaluation system for developing substances has not been established, there is an urgent need to develop a system for evaluating efficacy.
[0003] COVID-19, a new coronavirus reported to have originated in the Wuhan region of China in December 2019, typically presents with a 2 to 14-day incubation period followed by symptoms such as fever, respiratory symptoms like coughing or shortness of breath, and pneumonia; however, asymptomatic cases are also rare. The World Health Organization (WHO) declared COVID-19 a "pandemic," the highest alert level, and as of 21:00 on April 11, 2020, it is a disease with a fatality rate of 6.05%, comprising 1,715,224 confirmed cases and 103,827 deaths across 215 countries worldwide. The genome of the COVID-19 virus is an RNA virus structure in which a protein shell (capsid) containing the genome is surrounded by an envelope, and spike proteins, which are membrane glycoproteins, protrude like spikes on the surface. Functionally, it is divided into an S1 subunit that binds to receptors on host cells and an S2 subunit that fuses to the membrane; the S1 subunit contains a receptor binding domain (RBD) that binds to the ACE2 (Angiotensin converting enzyme 2) receptor on host cells. Since spike proteins play a crucial role in infecting the host by binding to the ACE2 receptor present in the host and penetrating into the host cell, most vaccines currently being administered or under development have been designed to induce neutralizing antibodies that neutralize spike proteins. However, various mutations have occurred in the spike proteins of the COVID-19 virus, leading to breakthrough infections by various variants, making countermeasures necessary. The problem to be solved
[0004] The present invention aims to provide an antibody or a fragment having immunological activity thereof for the detection of the COVID-19 virus or its variants, or for the prevention or treatment of COVID-19 virus infection. means of solving the problem
[0005] To achieve the above objective, the present invention provides an antibody specific to the COVID-19 virus or a variant thereof, or a fragment having the same immunological activity.
[0006] In addition, the present invention provides an isolated nucleic acid molecule encoding the antibody or a fragment having immunological activity thereof, a vector comprising the same, and a host cell transformed with said vector.
[0007] In addition, the present invention provides a method for producing an antibody specific to the COVID-19 virus or a variant thereof, or a fragment having the same’s immunological activity.
[0008] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of COVID-19 virus infection.
[0009] In addition, the present invention provides a composition for detecting the COVID-19 virus or a variant thereof.
[0010] In addition, the present invention provides a detection kit for the COVID-19 virus or its variants.
[0011] In addition, the present invention provides a method for detecting the COVID-19 virus or a variant thereof.
[0012] In addition, the present invention provides a method for providing information regarding the diagnosis of COVID-19 virus infection. Effects of the invention
[0013] The human antibody with enhanced binding affinity to the COVID-19 virus delta variant produced in the present invention and the fragment having immunological activity thereof bind with high affinity to all of the COVID-19 virus (SARS-CoV-2) wild type, COVID-19 virus alpha variant, COVID-19 virus beta variant, COVID-19 virus gamma variant, COVID-19 virus delta variant, COVID-19 virus kappa variant, and COVID-19 virus mu variant, so it can be utilized for the prevention or treatment of COVID-19 virus infection, and since various types of COVID-19 virus can be rapidly detected using the antibody and the fragment having immunological activity thereof, it can be usefully used for diagnosing infection with highly infective SARS-CoV-2 and for epidemiological investigation. Brief explanation of the drawing
[0014] Figure 1 shows the expression vector of the RBD antigen protein of the SARS-CoV-2 virus delta variant and the results of SDS-PAGE analysis of size and purity after expression and purification. Figure 2 is a schematic diagram of the construction of a yeast display library for selecting variants with enhanced binding affinity to the RBD antigen protein of SARS-CoV-2 virus delta variants. Figure 3 shows the results of analyzing the sub-libraries of each round screened through yeast cell wall display using FACS. Figure 4 shows the amino acid sequence of Fab antibody JS18.1, which exhibits high binding affinity to the RBD of the SARS-CoV-2 virus delta variant. Figure 5 shows a heavy chain and light chain expression vector for expressing an IgG form antibody of Fab antibody JS18.1, which shows high binding affinity to the RBD of the SARS-CoV-2 virus delta variant, and a figure confirming the expression and purification of the same in animal cells using an SDS-PAGE gel. Figure 6 shows the results of analyzing RBDs of SARS-CoV-2 virus wild type (WT), alpha variant, beta variant, gamma variant, delta variant, kappa variant, and mu variant by SDS-PAGE after expressing and purifying them as monomeric antigen proteins. Figure 7 shows the results of analyzing the binding affinity of the JS18.1 antibody and its parent antibody, BM-18 antibody, to the wild type (WT), alpha variant, beta variant, gamma variant, delta variant, kappa variant, and mu variant of the SARS-CoV-2 virus. Specific details for implementing the invention
[0015] Hereinafter, the present invention will be described in detail with reference to the attached drawings for embodiments of the present invention. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalents interpreted therefrom.
[0016] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.
[0017] All technical terms used in this invention, unless otherwise defined, are used in the sense generally understood by those skilled in the art in the relevant field of this invention. Additionally, while preferred methods or samples are described herein, similar or equivalents are also included within the scope of this invention. The contents of all publications cited as references in this specification are incorporated into this invention.
[0019] In one aspect, the present invention relates to an antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof, or a fragment having the immunological activity thereof.
[0020] In one embodiment, the variant may be an alpha variant, a beta variant, a gamma variant, a delta variant, a kappa variant, or a mu variant.
[0021] In one embodiment, the fragment having immunological activity may be any one selected from the group consisting of Fab, Fd, Fab', dAb, F(ab'), F(ab')2, scFv (single chain fragment variable), Fv, single-chain antibody, Fv dimer, complementarity determining region fragment, humanized antibody, chimeric antibody and diabody, and is more preferably scFv or Fab.
[0022] In one embodiment, the antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof or the fragment having immunological activity thereof according to the present invention may include a VH domain comprising CDRH (Complementarity determining regions Heavy chain) 1 having the amino acid sequence of SEQ ID NO. 1, CDRH2 having the amino acid sequence of SEQ ID NO. 2, and CDRH3 having the amino acid sequence of SEQ ID NO. 3.
[0023] In one embodiment, the antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof or the fragment having immunological activity thereof according to the present invention may include a VH domain comprising FR1 having the amino acid sequence of SEQ ID NO. 7, FR2 having the amino acid sequence of SEQ ID NO. 8, FR3 having the amino acid sequence of SEQ ID NO. 9, and FR4 having the amino acid sequence of SEQ ID NO. 10.
[0024] In one embodiment, the antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof or the fragment having immunological activity thereof according to the present invention may include a VL domain comprising a CDRL (Complementarity determining regions Light chain) 1 having the amino acid sequence of SEQ ID NO. 4, a CDRL 2 having the amino acid sequence of SEQ ID NO. 5, and a CDRL 3 having the amino acid sequence of SEQ ID NO. 6.
[0025] In one embodiment, the antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof or the fragment having immunological activity thereof according to the present invention may include a VL domain comprising FR1 having the amino acid sequence of SEQ ID NO. 11, FR2 having the amino acid sequence of SEQ ID NO. 12, FR3 having the amino acid sequence of SEQ ID NO. 13, and FR4 having the amino acid sequence of SEQ ID NO. 14.
[0026] In one embodiment, the antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof or the fragment having immunological activity thereof according to the present invention may comprise (i) a VH domain comprising CDRH1 having the amino acid sequence of SEQ ID NO. 1, CDRH2 having the amino acid sequence of SEQ ID NO. 2, and CDRH3 having the amino acid sequence of SEQ ID NO. 3; and (ii) a V domain comprising a VL domain comprising CDRL1 having the amino acid sequence of SEQ ID NO. 4, CDRL2 having the amino acid sequence of SEQ ID NO. 5, and CDRL3 having the amino acid sequence of SEQ ID NO. 6.
[0027] In one embodiment, the antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof or the fragment having immunological activity thereof according to the present invention may comprise a scFv comprising a VH domain comprising the amino acid sequence of SEQ ID NO. 15 and a VL domain comprising the amino acid sequence of SEQ ID NO. 16.
[0028] In one embodiment, the antibody specific to the coronavirus (SARS-CoV-2) or a variant thereof or the fragment having immunological activity thereof according to the present invention may include a CL containing the amino acid sequence of SEQ ID NO. 24, a CH1 containing the amino acid sequence of SEQ ID NO. 25, a CH2 containing the amino acid sequence of SEQ ID NO. 26, or a CH3 containing the amino acid sequence of SEQ ID NO. 27.
[0029] In one embodiment, the antibody specific to the COVID-19 virus (SARS-CoV-2) or a variant thereof or a fragment having immunological activity thereof according to the present invention may specifically bind to any one Receptor Binding Domain (RBD) selected from the group consisting of the COVID-19 virus (SARS-CoV-2) wild type, COVID-19 virus alpha variant, COVID-19 virus beta variant, COVID-19 virus gamma variant, COVID-19 virus delta variant, COVID-19 virus kappa variant, and COVID-19 virus mu variant; wherein the RBD of the COVID-19 virus wild type may include the amino acid sequence of SEQ ID NO. 17, the RBD of the COVID-19 virus alpha variant may include the amino acid sequence of SEQ ID NO. 18, the RBD of the COVID-19 virus beta variant may include the amino acid sequence of SEQ ID NO. 19, and the RBD of the COVID-19 virus gamma variant may include the amino acid sequence of SEQ ID NO. 20 The sequence may include, the RBD of the COVID-19 virus delta variant may include the amino acid sequence of SEQ ID NO. 21, the RBD of the COVID-19 virus kappa variant may include the amino acid sequence of SEQ ID NO. 22, and the RBD of the COVID-19 virus mu variant may include the amino acid sequence of SEQ ID NO. 23.
[0030] The above antibody is in the form of a whole antibody as well as includes functional fragments of the antibody molecule. The whole antibody has a structure comprising two full-length light chains and two full-length heavy chains, with each light chain connected to the heavy chain by a disulfide bond. A functional fragment of the antibody molecule refers to a fragment possessing antigen-binding function, and examples of antibody fragments include: (i) a Fab fragment consisting of the variable region (VL) of the light chain and the variable region (VH) of the heavy chain, and the constant region (CL) of the light chain and the first constant region (CH1) of the heavy chain; (ii) an Fd fragment consisting of the VH and CH1 domains; and (iii) an Fv fragment consisting of the VL and VH domains of a monoclonal antibody. (iv) a dAb fragment consisting of a VH domain (Ward ES et al., Nature 341:544-546 (1989)]; (v) a separated CDR region; (vi) a divalent fragment F(ab')2 fragment containing two linked Fab fragments; (vii) a single-stranded Fv molecule (scFv) linked by a peptide linker that links the VH domain and VL domain to form an antigen-binding site; (viii) a bispecific single-stranded Fv dimer (PCT / US92 / 09965); and (ix) a diabody WO94 / 13804, a multivalent or multispecific fragment produced by gene fusion.
[0031] In the present invention, the antibody or the fragment having immunological activity thereof may be selected from the group consisting of animal-derived antibodies, chimeric antibodies, humanized antibodies, human antibodies, and fragments having immunological activity thereof. The antibody may be produced recombinantly or synthetically.
[0032] Animal-derived antibodies, produced by immunizing animals with a desired antigen, can generally cause immune rejection when administered to humans for therapeutic purposes; chimeric antibodies were developed to suppress this rejection. Chimeric antibodies are created by using genetic engineering methods to replace the constant region of animal-derived antibodies—which causes anti-isotype reactions—with the constant region of human antibodies. While chimeric antibodies show significant improvement in anti-isotype reactions compared to animal-derived antibodies, they still carry potential side effects related to anti-idiotypic reactions because animal-derived amino acids remain in the variable region. Humanized antibodies were developed to address these side effects. They are produced by transplanting the Complementarity Determining Regions (CDRs), which play a crucial role in antigen binding within the variable region of chimeric antibodies, into a human antibody framework.
[0033] In CDR grafting technology for producing humanized antibodies, the most critical aspect is selecting an optimized human antibody capable of best accepting the CDR site of an animal-derived antibody; to achieve this, techniques such as antibody databases, crystal structure analysis, and molecular modeling are utilized. However, even when the CDR site of an animal-derived antibody is grafted onto an optimized human antibody scaffold, there are a significant number of cases where antigenic binding affinity is not preserved due to the presence of amino acids on the animal antibody scaffold that affect antigen binding. Therefore, the application of additional antibody engineering techniques to restore antigenic binding affinity is essential.
[0034] The above antibody or the fragment having immunological activity thereof may be isolated from a living organism (not present in the living organism) or non-naturally occurring, for example, may be produced synthetically or recombinantly.
[0035] In the present invention, the term "antibody" refers to a substance produced within the immune system by stimulation of an antigen; its type is not particularly limited and can be obtained naturally or unnaturally (e.g., synthetically or recombinantly). Antibodies are advantageous for mass expression and production because they are very stable and have a long half-life, both in vitro and in vivo. Furthermore, antibodies have a very high avidity because they inherently possess a dimer structure. A complete antibody has a structure comprising two full-length light chains and two full-length heavy chains, with each light chain connected to a heavy chain by a disulfide bond. The constant region of the antibody is divided into a heavy chain constant region and a light chain constant region. The heavy chain constant region has gamma (γ), mu (μ), alpha (α), delta (δ), and epsilon (ε) types, and has subclasses gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1), and alpha 2 (α2). The light chain constant region has kappa (κ) and lambda (λ) types.
[0036] In the present invention, the term "heavy chain" refers to a variable region domain V comprising an amino acid sequence having a variable region sequence sufficient to confer specificity to an antigen. H and 3 invariant domains C H1 , C H2 and C H3 It is interpreted to include both the full-length heavy chain containing the hinge and its fragments. Additionally, the term "light chain" refers to a variable region domain V containing an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen.L and invariant domain C L It is interpreted to mean that it includes all of the battlefield light chains and fragments thereof.
[0037] In the present invention, the term "variable region" or "variable domain" refers to a part of an antibody molecule that performs the function of specifically binding to an antigen and exhibits many variations in sequence, and the variable region contains complementary determining regions CDR1, CDR2, and CDR3. Between the CDRs, there exists a framework region (FR) that serves to support the CDR loop. The "complementary determining region" is a loop-shaped region involved in antigen recognition, and the specificity of the antibody for the antigen is determined as the sequence of this region changes.
[0038] The term "scFv (single chain fragment variable)" as used in the present invention refers to a single-chain antibody produced by expressing only the variable region of an antibody through genetic recombination, and refers to a single-chain antibody in which the VH region and the VL region of the antibody are connected by a short peptide chain. Unless otherwise specified or understood from the context, the term "scFv" is intended to include scFv fragments, including antigen-binding fragments. This is obvious to a person skilled in the art.
[0039] In the present invention, the term "complementarity determining region (CDR)" refers to the amino acid sequence of a hypervariable region of the heavy chain and light chain of an immunoglobulin. The heavy chain and light chain may each contain three CDRs (CDRH1, CDRH2, CDRH3 and CDRL1, CDRL2, CDRL3). The CDRs may provide major contact residues for the antibody to bind to an antigen or an epitope.
[0040] In the present invention, the terms "specifically binding" or "specifically recognizing" have the same meaning as commonly known to those skilled in the art, and refer to an antigen and an antibody specifically interacting to produce an immunological reaction.
[0041] In the present invention, the term "antigen-binding fragment" refers to a fragment of the entire immunoglobulin structure thereof, meaning a part of a polypeptide comprising a portion capable of binding to an antigen. For example, it may be scFv, (scFv) 2, scFv-Fc, Fab, Fab', or F(ab') 2, but is not limited thereto. Among the antigen-binding fragments, Fab comprises a variable region of the light chain and heavy chain, a constant region of the light chain, and a first constant region of the heavy chain (C H1 It has a structure containing ) and possesses one antigen-binding site. Fab' is heavy chain C H1It differs from Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the domain. F(ab')2 antibodies are generated when the cysteine residues in the hinge region of Fab' form disulfide bonds. Recombinant techniques for generating Fv fragments from minimal antibody fragments that possess only a heavy chain variable region and a light chain variable region are widely known in the art. Two-chain Fv has the heavy chain variable region and the light chain variable region connected by non-covalent bonds, while single-chain Fv generally has the heavy chain variable region and the single chain variable region connected by covalent bonds or directly at the C-terminus via a peptide linker, thereby forming a dimer-like structure similar to that of two-chain Fv. The linker may be a peptide linker composed of any 1 to 100 or 2 to 50 amino acids, and suitable sequences are known in the art. The above antigen-binding fragment can be obtained using a proteolytic enzyme (for example, Fab can be obtained by restricting the whole antibody with papain and F(ab')2 fragment can be obtained by cleaving it with pepsin), and can be produced through genetic recombination technology.
[0042] In the present invention, the term "hinge region" refers to a region included in the heavy chain of an antibody, C H1 and C H2 It refers to a region that exists between regions and functions to provide flexibility to the antigen binding site within the antibody. For example, the hinge may be derived from a human antibody, specifically, from IgA, IgE, or IgG, such as IgG1, IgG2, IgG3, or IgG4.
[0043] In one aspect, the present invention relates to an isolated nucleic acid molecule encoding an antibody of the present invention or a fragment having immunological activity thereof, a vector comprising said molecule, and a host cell transformed with said vector.
[0044] The nucleic acid molecules of the present invention may be isolated or recombinant and include DNA and RNA in single-stranded and double-stranded forms, as well as corresponding complementary sequences. In the case of nucleic acids isolated from natural sources, isolated nucleic acids are nucleic acids separated from surrounding genetic sequences present in the genome of the individual from which the nucleic acid was isolated. In the case of nucleic acids synthesized enzymatically or chemically from a template, such as PCR products, cDNA molecules, or oligonucleotides, the nucleic acids produced from these procedures may be understood as isolated nucleic acid molecules. Isolated nucleic acid molecules represent nucleic acid molecules in the form of separate fragments or as components of larger nucleic acid constructs. Nucleic acids are operably linked when arranged in a functional relationship with other nucleic acid sequences. For example, the DNA of a presequence or secretion leader is operably linked to the polypeptide DNA when the polypeptide is expressed as a preprotein, which is the form prior to secretion; a promoter or enhancer is operably linked to the coding sequence when it influences the transcription of the polypeptide sequence; or a ribosome binding site is operably linked to the coding sequence when positioned to facilitate translation. Generally, operably linked means that the DNA sequences to be linked are located adjacently, and in the case of a secretion leader, this means they exist adjacently within the same reading frame. However, enhancers do not need to be located adjacently. Linkage is achieved by ligation at a convenient restriction enzyme site. If such a site is not present, synthetic oligonucleotide adapters or linkers are used according to conventional methods.
[0045] The isolated nucleic acid molecule encoding the antibody of the present invention or a fragment having immunological activity thereof may undergo various modifications to the coding region within a range that does not alter the amino acid sequence of the antibody expressed from the coding region, due to codon degeneracy or considering the codons preferred by the organism to express said antibody; and may also undergo various modifications or alterations to parts excluding the coding region within a range that does not affect gene expression, and those skilled in the art will understand that such modified genes are also included within the scope of the present invention. That is, as long as the nucleic acid molecule of the present invention codes for a protein having equivalent activity, one or more nucleic acid bases may be modified by substitution, deletion, insertion, or a combination thereof, and these are also included within the scope of the present invention. The sequence of such nucleic acid molecule may be single-stranded or double-stranded, and may be a DNA molecule or an RNA (mRNA) molecule.
[0046] An isolated nucleic acid molecule encoding the antibody of the present invention or a fragment having immunological activity thereof according to the present invention may be inserted into an expression vector for protein expression. The expression vector typically comprises a protein in which the protein is functionally linked, i.e., functionally, to a regulatory or control sequence, a selection marker, any fusion partner, and / or additional elements. Under appropriate conditions, the antibody according to the present invention or the fragment having immunological activity thereof may be produced by a method of inducing protein expression by culturing a host cell transformed with nucleic acid, preferably an expression vector containing an isolated nucleic acid molecule encoding the antibody according to the present invention or a fragment having immunological activity thereof. Various suitable host cells, including mammalian cells, bacteria, insect cells, and yeast, may be used, but are not limited thereto. Methods for introducing exogenous nucleic acid into host cells are known in the art and will vary depending on the host cell used. Preferably, Escherichia coli, which has high industrial value due to its low production cost, may be produced as a host cell.
[0047] The vectors of the present invention include, but are not limited to, plasmid vectors, cosmid vectors, bacteriophage vectors, and viral vectors. Suitable vectors may include signal sequences or leader sequences for membrane targeting or secretion in addition to expression regulatory elements such as promoters, operators, start codons, stop codons, polyadenylation signals, and enhancers, and may be prepared in various ways depending on the purpose. The promoter of the vector may be constitutive or inducible. The signal sequences may include, but are not limited to, PhoA signal sequences, OmpA signal sequences, etc. when the host is Escherichia sp., α-amylase signal sequences, subtilisin signal sequences, etc. when the host is Bacillus sp., MFα signal sequences, SUC2 signal sequences, etc. when the host is yeast, and insulin signal sequences, α-interferon signal sequences, antibody molecule signal sequences, etc. when the host is an animal cell. Additionally, the vector may include a selection marker for selecting a host cell containing the vector, and if it is a replicable expression vector, it includes a replication origin.
[0048] In the present invention, the term “vector” refers to a carrier capable of inserting a nucleic acid sequence for introduction into a cell capable of replicating the nucleic acid sequence. The nucleic acid sequence may be exogenous or heterologous. Examples of vectors include, but are not limited to, plasmids, cosmids, and viruses (e.g., bacteriophages). Those skilled in the art may construct vectors using standard recombinant techniques (Maniatis, et al., *Molecular Cloning*, *A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1988; and Ausubel et al., *Current Protocols in Molecular Biology*, John, Wiley & Sons, Inc, NY, 1994, etc.).
[0049] In one embodiment, when producing the vector, expression control sequences such as a promoter, terminator, and enhancer, sequences for membrane targeting or secretion, etc., can be appropriately selected and combined in various ways according to the purpose, depending on the type of host cell to be used to produce the antibody.
[0050] In the present invention, the term "expression vector" means a vector comprising a nucleic acid sequence encoding at least a portion of a gene product to be transcribed. In some cases, the RNA molecule is subsequently translated into a protein, polypeptide, or peptide. The expression vector may include various regulatory sequences. Along with regulatory sequences that regulate transcription and translation, the vector and the expression vector may also include nucleic acid sequences that provide other functions.
[0051] In the present invention, the term "host cell" refers to any transgenic organism, including eukaryotes and prokaryotes, capable of replicating said vector or expressing a gene encoded by said vector. The host cell may be transfected or transformed by said vector, which refers to the process in which an exogenous nucleic acid molecule is delivered or introduced into the host cell.
[0052] In one embodiment, the host cell may be a bacterium or an animal cell, the animal cell line may be a CHO cell, an HEK cell, or an NSO cell, and the bacterium may be E. coli.
[0053] In one aspect, the present invention relates to a method for producing an antibody specific to the coronavirus or a variant thereof or a fragment having immunological activity thereof, comprising the steps of: a) culturing a host cell comprising a vector comprising the isolated nucleic acid molecule; and b) recovering an antibody or a fragment having immunological activity thereof from the host cell culture.
[0054] In one embodiment, after the step of recovering an antibody or a fragment having immunological activity thereof from a host cell culture, the method may further include a step of purifying the antibody or the fragment having immunological activity thereof.
[0055] The antibody of the present invention or the fragment having immunological activity thereof may be separated or purified by various methods known in the art. Standard purification methods include chromatography, electrophoresis, immunoassay, precipitation, dialysis, filtration, concentration, and chromatofocusing techniques. As known in the art, various natural proteins, such as bacterial proteins A, G, and L, bind to the antibody, and said proteins may be used for purification. Often, purification by a specific fusion partner may be possible.
[0056] After transforming the vector according to the present invention into a suitable host cell, e.g., E. coli or yeast cell, etc., and then culturing the transformed host cell, the antibody according to the present invention or a fragment having immunological activity thereof can be mass-produced. Appropriate culture methods and culture medium conditions depending on the type of host cell, etc., can be easily selected by a person skilled in the art from known techniques known to a person skilled in the art. The host cell is E. coli ( E. coli ) or Bacillus subtilis( Bacillus subtilis It could be a prokaryotic organism such as ). Also, Saccharomyces cerviscia ( Saccharomyces cerevisiae It may be a eukaryotic cell derived from yeast, insect cells, plant cells, or animal cells, such as ). More preferably, the animal cell may be an autologous or allogeneic animal cell. The transformant produced by introducing the vector into an autologous or allogeneic animal cell may be administered to an individual and used for cell therapy to treat cancer, etc. Any method known to those skilled in the art may be used for the method of introducing the vector into the host cell. Other organisms, including transgenic (e.g., genetically engineered) mice or other mammals, may be used to produce the antibody of the present invention or a fragment having immunological activity thereof (see, for example, US 6,300,129). For example, it is known that mice engineered by replacing only the variable regions of mouse immune genes (heavy chain V, D, and J segments, and light chain V and J segments) with corresponding human variable sequences can be used to mass-produce high-affinity antibodies having human variable sequences (see, e.g., US 6,586,251; US 6,596,541, and US 7,105,348).
[0057] In one aspect, the present invention relates to a pharmaceutical composition for the prevention or treatment of COVID-19 virus infection comprising an antibody specific to the COVID-19 virus or a variant thereof or a fragment having immunological activity thereof.
[0058] In one embodiment, the coronavirus infection may also be referred to as novel coronavirus infection or COVID-19.
[0059] In one embodiment, the COVID-19 virus infection may be caused by infection with COVID-19 virus (SARS-CoV-2) wild type, COVID-19 virus alpha variant, COVID-19 virus beta variant, COVID-19 virus gamma variant, COVID-19 virus delta variant, COVID-19 virus kappa variant, or COVID-19 virus mu variant.
[0060] In the present invention, the term "prevention" refers to any act of suppressing or delaying the occurrence, spread, and recurrence of COVID-19 virus infection by administering a composition according to the present invention.
[0061] The term "treatment" as used in this invention refers to any act of improving or beneficially altering the symptoms of COVID-19 virus infection and its complications through the administration of the composition according to this invention. A person skilled in the art to which this invention pertains would be able to determine the precise criteria for diseases for which the composition of this invention is effective, and to assess the degree of improvement, enhancement, and treatment, by referring to materials provided by organizations such as the Korean Medical Association.
[0062] In the present invention, the term "therapeutically effective amount" used in combination with the active ingredient refers to an amount effective for preventing or treating COVID-19 virus infection, and the therapeutically effective amount of the composition of the present invention may vary depending on various factors, such as the method of administration, the target site, and the patient's condition. Therefore, when used in humans, the dosage should be determined as an appropriate amount by considering both safety and efficacy. It is also possible to estimate the amount used in humans from the effective amount determined through animal experiments. Such matters to be considered when determining the effective amount are described, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and EW Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.
[0063] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used in the present invention, the term "pharmaceuticalally effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects. The effective dose level may be determined based on factors including the patient's health status, the severity of COVID-19 infection, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. Considering all of the above factors, it is important to administer an amount that obtains maximum effect with a minimum amount without side effects, and this can be easily determined by a person skilled in the art.
[0064] The pharmaceutical composition of the present invention may include a carrier, a diluent, an excipient, or a combination of two or more of these commonly used in biological preparations. As used in the present invention, the term "pharmaceutical acceptable" means exhibiting properties that are not toxic to cells or humans exposed to the composition. The carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, and may be used, for example, compounds listed in Merck Index, 13th ed., Merck & Co. Inc., saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed. Additionally, diluents, dispersants, surfactants, binders, and lubricants may be added to formulate the composition into primary formulations such as aqueous solutions, suspensions, and emulsions, as well as pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or component using appropriate methods in the field or methods disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
[0065] In one embodiment, the pharmaceutical composition may be one or more formulations selected from the group comprising oral formulations, topical preparations, suppositories, sterile injectable solutions, and sprays, and an oral or injectable formulation is more preferred.
[0066] As used in the present invention, the term "administration" means providing a specific substance to an individual or patient by any appropriate method. Depending on the intended method, it may be administered parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or locally as an injectable formulation) or orally. The dosage varies depending on the patient's body weight, age, gender, health status, diet, time of administration, method of administration, excretion rate, and severity of the disease. Liquid formulations for oral administration of the composition of the present invention include suspensions, liquid formulations, emulsions, syrups, etc. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories, etc. The pharmaceutical composition of the present invention may also be administered by any device capable of delivering the active substance to target cells. Preferred modes of administration and formulations include intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, drip infusions, etc. Injectables can be prepared using aqueous solvents such as physiological saline solution and Ringer's solution, vegetable oils, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), non-aqueous solvents, and may include pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
[0067] The term "individual" used in the present invention refers to any animal including monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, bats, camels, rats, rabbits, or guinea pigs, including humans, that has developed or may develop the COVID-19 virus infection, and "specimen" may be droplets, sputum, whole blood, plasma, serum, urine, or saliva separated therefrom.
[0068] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, and talc. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight with respect to the composition, but is not limited thereto.
[0069] In one aspect, the present invention relates to a composition for detecting the COVID-19 virus or a variant thereof, comprising an antibody specific to the COVID-19 virus or a variant thereof or a fragment having the immunological activity thereof.
[0070] It is preferable that the antibodies of the present invention or fragments having immunological activity thereof used in the detection (diagnostic) composition be labeled so as to be detectable. Various methods available for labeling biomolecules are well known to those skilled in the art and are considered within the scope of the present invention. Such methods are described in Tijssen, 'Practice and theory of enzyme immunoassays', Burden, RHand von Knippenburg (Eds), Volume 15 (1985), 'Basic methods in molecular biology'; Davis LG, Dibmer MD; Battey Elsevier (1990), Mayer et al., (Eds) 'Immunochemical methods in cell and molecular biology', Academic Press, London (1987), or in the series 'Methods in Enzymology', Academic Press, Inc.
[0071] There are many different marking methods and markings known to those skilled in the art. Examples of types of markings that can be used in the present invention include enzymes, radioactive isotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds, and bioluminescent compounds.
[0072] Commonly used labels include fluorescent substances (e.g., fluorescein, rhodamine, Texas Red, etc.), enzymes (e.g., horseradish peroxidase, β-galactosidase, alkaline phosphatase), and radioactive isotopes (e.g., 32 P or 125 This includes I), biotin, digoxigenin, colloidal metals, and chemiluminescent or bioluminescent compounds (e.g., dioxetane, luminol, or acridinium). Labeling methods such as the covalent bonding of enzymes or biotinyl groups, iodination, phosphorylation, and biotinylation are well known in the field.
[0073] Detection methods include, but are not limited to, autoradiography, fluorescence microscopy, and direct and indirect enzymatic reactions. Commonly used detection analysis methods include radioisotope or non-radioisotope methods. These include Western blotting, overlay analysis, RIA (Radioimmuno Assay), IRMA (Immune Radioimmunometric Assay), EIA (Enzyme Immuno Assay), ELISA (Enzyme Linked Immuno Sorbent Assay), FIA (Fluorescent Immuno Assay), and CLIA (Chemioluminescent Immune Assay).
[0074] In one aspect, the present invention relates to a COVID-19 virus or variant detection kit comprising a composition for detecting the COVID-19 virus or a variant thereof.
[0075] In one embodiment, the kit may include a composition for detecting the COVID-19 virus or a variant thereof according to the present invention and a reagent for detecting the antigen-antibody complex. The reagent for detecting the antigen-antibody complex includes a reagent for radioimmunoassay, ELISA (Enzyme-linked immunosorbent assay), or immunofluorescence analysis.
[0076] In one embodiment, detection of an antigen-antibody complex can be achieved by immunoelectrophoresis such as Ouchterlony plates, Western blots, Crossed IE, Rocket IE, Fused Rocket IE, and Affinity IE, which can simply detect antibodies and / or antigens through antigen-antibody binding. The reagents or substances used in these methods are known and may be detected, for example, through an antigen-antibody reaction, a substrate that specifically binds to the antigen, a nucleic acid or peptide aptamer, a receptor or ligand or cofactor interacting with the complex, or by using a mass spectrometer. The reagents or substances that specifically interact with or bind to the antigen-antibody complex of the present invention may be used in combination with a chip method or nanoparticles. The method of immunoassay or immunostaining described above is Enzyme Immunoassay, ET Maggio, ed., CRC Press, Boca Raton, Florida, 1980; It is described in Gaastra, W., Enzyme-linked immunosorbent assay (ELISA), in Methods in Molecular Biology, Vol. 1, Walker, JM ed., Humana Press, NJ, 1984, etc. By analyzing the intensity of the final signal from the immunoassay process described above, that is, by performing a signal comparison with a normal sample, the presence of the COVID-19 virus in the subject can be detected, thereby diagnosing whether the subject is infected with the COVID-19 virus.
[0077] In one aspect, the present invention relates to a method for detecting a COVID-19 virus or a variant thereof, comprising: (a) contacting a sample separated from a specimen with an antibody specific to the COVID-19 virus or a variant thereof or a fragment having immunological activity thereof; and (b) detecting the formation of an antigen-antibody complex.
[0078] In one embodiment, the variant of the COVID-19 virus may be an alpha variant, a beta variant, a gamma variant, a delta variant, a kappa variant, or a mu variant.
[0079] In one aspect, the present invention relates to a method for providing information regarding the diagnosis of a COVID-19 virus infection, comprising: (a) contacting a sample separated from a specimen with an antibody specific to the COVID-19 virus of the present invention or a variant thereof, or a fragment having immunological activity thereof, to form an antigen-antibody complex; and (b) detecting the formation of said complex.
[0080] In one embodiment, the COVID-19 virus infection may be caused by infection with COVID-19 virus (SARS-CoV-2) wild type, COVID-19 virus alpha variant, COVID-19 virus beta variant, COVID-19 virus gamma variant, COVID-19 virus delta variant, COVID-19 virus kappa variant, or COVID-19 virus mu variant.
[0082] The present invention will be explained in more detail through the following examples. However, the following examples are intended only to illustrate the content of the present invention and do not limit the present invention.
[0084] Example 1. Production of RBD (Receptor Binding Domain) antigen of SARS-CoV-2 virus delta variant
[0085] Antigens were prepared to induce directional evolution of antibodies against the delta (B.1.617.2) variant, which is known to be the most transmissible among various COVID-19 virus variants. Specifically, to create antibodies that bind to the RBD (Receptor Binding Domain) region, which is known to be important for the virus to bind to the surface of the ACE2 (Angiotensin converting enzyme 2) receptor present in host cells and infect the host, the RBD region of the SARS-CoV-2 delta variant was prepared as an antigen. In addition, animal cell expression vectors were prepared to produce a dimeric antigen by fusing a GST tag to the above antigen, in order to create an antigen more suitable for antibody screening using a flow cytometer. After mixing each vector into 30 ml of Freestyle 293 expression medium (Gibco, 12338-018), mix PEI (Polyethylenimine) (Polyscience, 23966) and each vector in a 4:1 ratio, leave at room temperature for 20 minutes, and then the previous day 2x10 6Expi293F animal cells, subcultured in 300 ml at a density of cells / ml, were treated for transfection and incubated in a shaking CO2 incubator at 37°C, 125 rpm, and 8% CO2 for 7 days. After centrifugation, only the supernatant was collected. Subsequently, equilibrium was achieved using 25x PBS, and the solution was filtered through a 0.2 μm Merck Millipore bottle-top filter. 1 ml of GSH resin was added to the filtered culture medium, and the mixture was stirred at 4°C for 16 hours. Afterward, the resin was recovered via a column, washed with 5 ml of PBS, and eluted with 4 ml of 50 mM Tris-HCl & 10 mM reduced glutation (pH 8.0) (SIGMA). After performing a buffer change with PBS, the size and purity of the SARS-CoV-2 virus Delta-RBD-GST antigen protein purified under non-reducing (Non) and reducing (RE) conditions, respectively, were analyzed by SDS-PAGE (Fig. 1). In addition, the SARS-CoV-2 virus Delta-RBD-GST was labeled with the Alexa488 fluorescent molecule for use in screening using a flow cytometer.
[0087] Example 2. Preparation of a library for screening antibodies with enhanced binding affinity to the RBD of the SARS-CoV-2 virus delta variant
[0088] To efficiently select human antibodies with enhanced binding affinity to the SARS-CoV-2 virus Delta variant, a library containing 0.2% random mutations was constructed via Error-prone PCR on the variable regions of BM 18 and BM 23 (human antibodies binding to the wild-type COVID-19 virus-RBD region, discovered by the inventors through prior research) displayed in Fab form on yeast. The constructed DNA library was then subjected to electroporation using a MicroPulser Electroporator (Bio-Rad) with 8 μg of a vector encoding the yeast cell wall anchoring protein Aga2 and the transformation selection marker gene (Trp1) in the yeast species Saccharomyces cerevisiae ( Saccharomyces cerevisiae After delivering 400 μl of Competent cells, the cells were cultured in 500 ml of SD medium [Difco Yeast Nitrogen Base (BD) 6.7 g / l, Bactocasamino Acid (BD) 5.0 g / l, Na2HPO4 (JUNSEI) 5.4 g / l, NaH2PO4·H2O (SAMCHUN) 8.56 g / l, and Glucose (DUKSAN) 20 g / l] to selectively keep only the transformed yeast strains alive, resulting in BM18 and BM23, each at 7.5 × 10⁶ 7 and 1.0×10 8 A yeast display library with ensured diversity was created (Fig. 2).
[0090] Example 3. Human antibody screening with enhanced binding affinity to COVID-19 virus delta variant
[0091] To discover human antibodies that bind to various COVID-19 variants, screening for human antibodies binding to the RBD region of the dimeric COVID-19 virus delta variant (SARS-CoV-2 virus delta) labeled with the Alexa488 fluorescent molecule was performed using a flow cytometer with a yeast-displayed Fab antibody library. Specifically, 5.5 × 10⁶ of the yeast library prepared in Example 2 above8 After culturing dog cells in 100 ml of tryptophan-deficient SD medium at 30°C for 16 hours, 7×10 8 Canine cells were cultured in 100 ml of SG medium [Difco Yeast Nitrogen Base (BD) 6.7 g / l, Bactocasamino Acid (BD) 5.0 g / l, Na2HPO4 (JUNSEI) 5.4 g / l, NaH2PO4·H2O (SAMCHUN) 8.56 g / l, Galactose (Sigma-Aldrich) 20 g / l] at 20°C for 48 hours to enhance the expression levels of the library. Among the cultured cells, 1×10 8 After centrifuging the cells at 14,000 ×g for 30 seconds at 4°C and removing the supernatant, the cells were washed with 1 ml of PBSB (1×PBS, 0.1% bovine serum albumin (Gibco)) (pH 7.4). Subsequently, the cells were incubated for 1 hour in 1 ml of PBSB (pH 7.4) diluted with 200 nM Alexa488-conjugated SARS-CoV2 delta RBD prepared in Example 1 and 1000:1 anti-FLAG-iFlor (GenScript). After incubation, the cells were washed with 1 ml of PBSB (pH 7.4) and resuspended in 1 ml of PBSB (pH 7.4) to induce binding with Alexa488-conjugated SARS-CoV2 delta RBD, and the cells exhibiting high fluorescence signals were separated using a flow cytometer (Bio-Rad S3 sorter, Bio-Rad). The recovered sub-library was subjected to a total of 5 rounds of screening processes while reducing the concentration of Alexa488-conjugated SARS-CoV2 delta RBD in the same manner to concentrate cells displaying Fab variants with excellent binding affinity to SARS-CoV2 delta RBD (Fig. 3), and 50 individual clonal antibodies were obtained.
[0093] Example 4. Confirmation of the gene sequence of the COVID-19 virus delta variant binding antibody variant
[0094] To confirm the gene sequences of the scFv variant clones obtained in Example 3 above, DNA base sequences were analyzed using Sanger sequencing. As a result, it was confirmed that all 50 individual clone antibodies submitted for analysis were Fab antibodies with a single sequence, and since it was confirmed that this originated from the parent antibody BM 18, it was named JS18.1 (Fig. 4).
[0096] Example 5 Production and Purification of Antibodies Against COVID-19 Virus Delta Variant-Conjugated Fab Variant
[0097] To confirm whether the Fab antibody variant JS18.1 selected in the above example possesses binding affinity to the RBD of the COVID-19 virus delta variant in IgG form, heavy chain and light chain expression vectors were constructed, respectively; the heavy chain and light chain genes of the corresponding variant were mixed in a 1:1 ratio, and PEI and the variant gene were mixed in a 4:1 ratio and left at room temperature for 20 minutes, and then the previous day 2x10 6Expi293F animal cells, subcultured at a density of cells / ml, were transfected using PEI (Polyethylenimine, Polyscience, 23966). Subsequently, the cells were cultured in a CO2-stirred incubator at 37°C, 125 rpm, and 8% CO2 for 7 days, and the supernatant was collected after centrifugation. Equilibration was performed using 25xPBS, and the solution was filtered using a bottle-top filter with a 0.2 μm filter (Merck Millipore). 500 μl of Protein A resin was added to the filtered culture medium and stirred at 4°C for 16 hours, after which the resin was recovered through a column. The recovered resin was washed with 5 ml of PBS, eluted with 3 ml of 100 mM glycine buffer (pH 2.7), and neutralized with 1 M Tris-HCl (pH 8.0). The size and purity of the purified antibodies were analyzed by SDS-PAGE after changing the buffer to PBS using centrifugal filter units 3K (Merck Millipore) (Fig. 5).
[0099] Example 6. Analysis of binding affinity with various COVID-19 virus variants
[0100] 6-1. Production of Monomeric RBD Proteins of Various COVID-19 Virus Variants
[0101] To confirm the binding ability of the novel antibody JS18.1 discovered through the above example to various variants of the coronavirus, monomeric forms of RBD proteins of the coronavirus (SARS-CoV-2) wild type, coronavirus alpha variant, coronavirus beta variant, coronavirus gamma variant, coronavirus delta variant, coronavirus kappa variant, and coronavirus mu variant were expressed. Specifically, animal cell expression vectors for expressing proteins fused with a polyhistidine tag were constructed, and each vector was mixed into 30 ml of Freestyle 293 expression medium (Gibco, 12338-018). Then, PEI (Polyethylenimine) (Polyscience, 23966) and the RBD variant gene were mixed in a 4:1 ratio, incubated at room temperature for 20 minutes, and the previous day 2x10 6 Expi293F animal cells subcultured at a density of cells / ml were treated for transfection and incubated in a shaking CO2 incubator at 37°C, 125 rpm, and 8% CO2 for 7 days. After centrifugation, only the supernatant was collected. Subsequently, equilibrium was achieved using 25x PBS, and the solution was filtered through a 0.2 μm filter (Merck Millipore) using a bottle-top filter. 1 ml of Ni-NTA resin was added to the filtered culture medium, and the mixture was stirred at 4°C for 16 hours. Afterward, the resin was recovered via a column, washed with 5 ml of PBS, and eluted with 250 mM imidazole (pH 8.0). After performing a buffer change with PBS using 3K centrifugal filter units (Merck Millipore), the size and purity of the purified antigen proteins were analyzed by SDS-PAGE (Fig. 6).
[0103] 6-2. Analysis of Binding Affinity for Various COVID-19 Virus Variants
[0104] In order to analyze the antibody binding ability of JS18.1, a Fab variant that binds to the COVID-19 virus delta variant derived through the above example, to the RBD of various COVID-19 virus variants, an ELISA experiment was conducted on the JS18.1 antibody, which was expressed and purified in the above example, and its parent antibody BM18, using the antigen proteins prepared in 6-1 above. Specifically, monomeric forms of the COVID-19 virus wild type, COVID-19 virus alpha variant, COVID-19 virus beta variant, COVID-19 virus gamma variant, COVID-19 virus delta variant, COVID-19 virus kappa variant, and COVID-19 virus mu variant of Example 6-1, diluted to 4 μg / ml in 0.05 M Na2CO3 pH 9.6, were each immobilized by incubating 50 μl of each into different Flat Bottom Polystyrene High Bind 96-well microplates (costar) at 4°C for 16 hours, and then blocked with 100 μl of 4% skim milk (GenomicBase) and 0.05% PBST (pH 7.4) at room temperature for 2 hours. After washing four times with 180 μl of 0.05% PBST, 50 μl of serially diluted JS18.1 antibody and BM18 antibody with 1% skim milk (in 0.05% PBST) were dispensed into each well and incubated at room temperature for 1 hour. After the washing process, antibody reactions were carried out at room temperature for 1 hour using 50 μl of anti-Human HRP conjugate (Jackson Immunoresearch) and a washing process was performed.Subsequently, 50 μl of 1-Step Ultra TMB-ELISA Substrate Solution (Thermo Fisher Scientific) was added to induce color development, and 50 μl of 2 M H2SO4 was added to terminate the reaction. The absorbance was then analyzed using an Epoch microplate spectrophotometer (BioTek). As a result, the JS18.1 antibody of the present invention bound with high affinity to all COVID-19 virus variants, including the wild type, alpha variant, beta variant, gamma variant, delta variant, kappa variant, and mu variant, and was found to have significantly increased binding characteristics compared to its parent antibody, BM18 (Fig. 7).
Claims
Claim 1 An antibody specific to any one or more viruses selected from the group consisting of the coronavirus (SARS-CoV-2) and its alpha, beta, gamma, delta, kappa, and mu variants, comprising a VH domain including a CDRH (Complementarity determining regions Heavy chain) 1 consisting of an amino acid sequence represented by SEQ ID NO. 1; a CDRH2 consisting of an amino acid sequence represented by SEQ ID NO. 2; and a CDRH3 consisting of an amino acid sequence represented by SEQ ID NO. 3; and a CDRL (Complementarity determining regions Light chain) 1 consisting of an amino acid sequence represented by SEQ ID NO. 4; a CDRL2 consisting of an amino acid sequence represented by SEQ ID NO. 5; and a CDRL3 consisting of an amino acid sequence represented by SEQ ID NO. 6; or a fragment having immunological activity, comprising a CDR of said antibody. Claim 2 delete Claim 3 In claim 1, the fragment having immunological activity comprises an antibody specific to one or more viruses selected from the group consisting of the coronavirus (SARS-CoV-2), which is selected from the group consisting of Fab, Fd, Fab', F(ab'), F(ab')2, scFv (single chain fragment variable), Fv, Fv dimer, humanized antibody, chimeric antibody, and diabody, and the alpha, beta, gamma, delta, kappa, and mu variants of the coronavirus; or a fragment having immunological activity comprising a CDR of the antibody. Claim 4 delete Claim 5 In claim 1, the antibody is an antibody specific to any one or more viruses selected from the group consisting of a COVID-19 virus (SARS-CoV-2) comprising a VH domain including FR1 having the amino acid sequence of SEQ ID NO. 7, FR2 having the amino acid sequence of SEQ ID NO. 8, FR3 having the amino acid sequence of SEQ ID NO. 9, and FR4 having the amino acid sequence of SEQ ID NO. 10, and alpha, beta, gamma, delta, kappa, and mu variants of said COVID-19 virus; or a fragment comprising a CDR of said antibody and having the same immunological activity. Claim 6 delete Claim 7 In claim 1, the antibody is an antibody specific to any one or more viruses selected from the group consisting of a COVID-19 virus (SARS-CoV-2) comprising a VL domain comprising FR1 having the amino acid sequence of SEQ ID NO. 11, FR2 having the amino acid sequence of SEQ ID NO. 12, FR3 having the amino acid sequence of SEQ ID NO. 13, and FR4 having the amino acid sequence of SEQ ID NO. 14, and alpha, beta, gamma, delta, kappa, and mu variants of the COVID-19 virus; or a fragment comprising a CDR of the antibody and having the same immunological activity. Claim 8 delete Claim 9 In claim 1, the antibody is an antibody specific to any one or more viruses selected from the group consisting of a coronavirus (SARS-CoV-2) comprising a scFv comprising a VH domain comprising the amino acid sequence of SEQ ID NO. 15 and a VL domain comprising the amino acid sequence of SEQ ID NO. 16, and alpha, beta, gamma, delta, kappa, and mu variants of the coronavirus; or a fragment comprising a CDR of the antibody having immunological activity. Claim 10 An isolated nucleic acid molecule comprising the antibody of claim 1 or the CDR of said antibody, encoding a fragment having the same immunological activity. Claim 11 A vector containing the isolated nucleic acid molecule of claim 10. Claim 12 A host cell isolated from an individual that has been transformed with the vector of claim 11. Claim 13 a) a step of culturing a host cell comprising a vector comprising the isolated nucleic acid molecule of claim 10; and b) a step of recovering an antibody or a fragment having immunological activity thereof from a host cell culture, wherein the antibody is specific to any one or more viruses selected from the group consisting of the coronavirus (SARS-CoV-2) and the alpha, beta, gamma, delta, kappa, and mu variants of the coronavirus; or a method for producing a fragment having immunological activity thereof comprising a CDR of said antibody. Claim 14 delete Claim 15 delete Claim 16 An antibody specific to any one or more viruses selected from the group consisting of the COVID-19 virus (SARS-CoV-2) of claim 1 and said COVID-19 virus variants alpha, beta, gamma, delta, kappa, and mu; or a composition for detecting any one or more viruses selected from the group consisting of the COVID-19 virus (SARS-CoV-2) and said COVID-19 virus variants, comprising a fragment having immunological activity and including a CDR of said antibody. Claim 17 One or more virus detection kits selected from the group consisting of a COVID-19 virus (SARS-CoV-2) comprising the composition of claim 16, and alpha, beta, gamma, delta, kappa, and mu variants of said COVID-19 virus. Claim 18 (a) a step of contacting a sample separated from a specimen with an antibody specific to one or more viruses selected from the group consisting of the COVID-19 virus (SARS-CoV-2) of claim 1 and its alpha, beta, gamma, delta, kappa, and mu variants, or a fragment having immunological activity comprising a CDR of said antibody; and (b) a step of detecting the formation of an antigen-antibody complex, comprising the step of detecting one or more viruses selected from the group consisting of the COVID-19 virus (SARS-CoV-2) and its alpha, beta, gamma, delta, kappa, and mu variants. Claim 19 delete Claim 20 (a) a step of forming an antigen-antibody complex by contacting a sample separated from a specimen with an antibody specific to one or more viruses selected from the group consisting of the COVID-19 virus (SARS-CoV-2) of claim 1 and its alpha, beta, gamma, delta, kappa, and mu variants, or a fragment having immunological activity comprising a CDR of said antibody; and (b) a step of detecting the formation of said complex, comprising a step of the COVID-19 virus (SARS-CoV-2) and one or more viruses selected from the group consisting of said COVID-19 virus's alpha, beta, gamma, delta, kappa, and mu variants. Claim 21 delete
Citation Information
Patent Citations
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
US10787501B1
